|
Mimetogen Pharmaceuticals Enters Into Licensing Agreement with Allergan to Develop and Commercialize Tavilermide (MIM-D3) Topical Dry Eye Treatment
|
04 November 2015 |
|
Mimetogen Pharmaceuticals Announces Expiration of Exclusive Option Agreement with Bausch + Lomb
|
11 September 2014 |
|
Mimetogen Pharmaceuticals Announces Topline Results of Its Second Clinical Study with MIM-D3 for the Treatment of Dry Eye Syndrome
|
09 September 2014 |
|
Mimetogen Pharmaceuticals Inc. Announces Initiation of a Phase 3 Clinical Trial with MIM-D3 to Treat Dry Eye Syndrome
|
10 October 2013 |
|
Bausch + Lomb Acquires Option to License New Compound to Treat Dry Eye Syndrome (DES)
|
18 July 2013 |
|
Mimetogen Pharmaceuticals Inc. Announces Issuance of Key US Patent Protecting the Use of MIM-D3 to Treat Dry Eye Syndrome
|
28 November 2012 |
|
Mimetogen Pharmaceuticals Inc. Appoints Kim Brazzell, Ph.D. as Chief Medical Officer
|
05 January 2012 |
|
Mimetogen Pharmaceuticals Inc. Announces Positive Top Line Data from Phase II Clinical Trial of MIM-D3 for Dry Eye Syndrome
|
26 June 2011 |
|
Mimetogen Pharmaceuticals Announces Completion of Series B Financing and Enrollment of 100th Patient in Phase II Trial
|
25 February 2011 |
|
Mimetogen Pharmaceuticals Announces Initiation of Phase II Clinical Trial of Novel NGF Mimetic in Patients with Dry Eye Syndrome
|
22 November 2010 |
